EP3925607
Lyfjasamsetningar til meðhöndlunar á slímseigjusjúkdóms-himnuleiðnistillis-miðluðum sjúkdómum
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
14.4.2015EP published:
28.6.2023EP application number:
21175519.4
EP translation filed:
28.8.2023Grant published:
15.9.2023EPO information:
European Patent Register
Max expiry date:
13.4.2035Expiry date:
13.4.2026Next due date:
30.4.2026
Title in English:
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASESLanguage of the patent:
English
Timeline
Today
14.4.2015EP application
28.6.2023EP Publication
28.8.2023Translation submitted
15.9.2023Registration published
13.4.2026Expires
Owner
Name:
Vertex Pharmaceuticals IncorporatedAddress:
50 Northern Avenue, Boston, MA 02210, US
Inventor
Name:
PHENIX, Brian DeanAddress:
Acton 01720, US
Name:
BAGNOL, Laurent Jean-claudeAddress:
Burlington 01803, US
Name:
BRODEUR, Geoffrey GlenAddress:
Boston 02210, US
Name:
CHANDRAN, SachinAddress:
Somerville 02144, US
Name:
DOKOU, EleniAddress:
Cambridge 02140, US
Name:
FERRIS, Lori AnnAddress:
Medford 02155, US
Name:
KNEZIC, DragutinAddress:
Watertown 02472, US
Name:
MCCARTY, Katie LynnAddress:
Watertown 02472, US
Name:
MEDEK, AlesAddress:
Winchester 01890, US
Name:
WAGGENER, Sara A.Address:
N. Billerica 01862, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201461979848 PDate:
15.4.2014Country:
US
Number:
201462059287 PDate:
3.10.2014Country:
US
Classification
Categories:
A61K 31/404, A61K 9/14, C07D 209/04, C07D 215/00, A61K 45/06, A61K 9/20, A61K 31/47, A61K 9/16, A61P 11/00
Annual fees
Number
Paid
Expires
Payer
Number: 10
Paid: 19.3.2024
Expires: 13.4.2025
Payer: Árnason Faktor ehf.
Number: 11
Paid: 14.4.2025
Expires: 13.4.2026
Payer: Árnason Faktor ehf.